Publication at First Faculty of Medicine |
2021
Abstract
The article shortly summarizes the status of candesartan, an AT1 blocker, in the treatment of cardiovascular diseases and emphasizes the main studies with this molecule in hypertension and heart failure. The advantages of candesartan comprise of positive clinical data not only in arterial hypertension but also in chronic heart failure.
Indications and contraindications of use in clinical practice are mentioned in the conclusion.